Evidence map›Paper›PMID 42656883›Full record

ArticleCase reports in hematology2026

Sustained Erythroid Response to Eltrombopag in Low-Risk Myelodysplastic Neoplasms With Severe Anemia and Thrombocytopenia: A Case Report.

Ambra Di Veroli, Cinzia De Gregoris, Roberta Laureana, Matteo Caridi, Valentina Panichi, Monica Poscente, Esther Natalie Oliva, Roberto Latagliata

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Case reports in hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ambra Di VeroliUOC Hematology, ASL Viterbo, Santa Rosa Hospital, Viterbo, Italy.
Cinzia De GregorisUOC Hematology, ASL Viterbo, Santa Rosa Hospital, Viterbo, Italy.
Roberta LaureanaUOC Hematology, ASL Viterbo, Santa Rosa Hospital, Viterbo, Italy.
Matteo CaridiUOC Hematology, ASL Viterbo, Santa Rosa Hospital, Viterbo, Italy.
Valentina PanichiUOC Clinical Diagnostic, ASL Viterbo, Santa Rosa Hospital, Viterbo, Italy.
Monica PoscenteUOSD Laboratory of Medical Genetics, ASL Viterbo, Santa Rosa Hospital, Viterbo, Italy.
Esther Natalie OlivaHematology Department, London North West University Healthcare NHS Trust, London, UK.ORCID https://orcid.org/0000-0001-9238-5734
Roberto LatagliataUOC Hematology, ASL Viterbo, Santa Rosa Hospital, Viterbo, Italy.ORCID https://orcid.org/0000-0002-7741-862X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Eltrombopag has been already employed for thrombocytopenia in myelodysplastic neoplasms (MDS), but its role and efficacy in improving other cytopenias are still unknown. In October 2020, a 58-year-old low-risk MDS male with transfusion-dependent/erythropoietin-resistant anemia and severe thrombocytopenia (platelets [PLTs]: 19 × 10

Indexed as

case reporteltrombopagerythroid responsemyelodysplastic neoplasmsthrombocytopenia

Identifiers

PMID42656883
PMCPMC13507826

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.